Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
DCTH's Cash to Debt is ranked higher than
91% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. DCTH: No Debt )
DCTH' s 10-Year Cash to Debt Range
Min: 25.24   Max: No Debt
Current: No Debt

Equity to Asset 0.76
DCTH's Equity to Asset is ranked higher than
83% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. DCTH: 0.76 )
DCTH' s 10-Year Equity to Asset Range
Min: 0.66   Max: 0.81
Current: 0.76

0.66
0.81
Interest Coverage No Debt
DCTH's Interest Coverage is ranked higher than
94% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. DCTH: No Debt )
DCTH' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: -14.70
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1805.61
DCTH's Operating margin (%) is ranked lower than
53% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. DCTH: -1805.61 )
DCTH' s 10-Year Operating margin (%) Range
Min: -15569.65   Max: -1805.8
Current: -1805.61

-15569.65
-1805.8
Net-margin (%) -1625.91
DCTH's Net-margin (%) is ranked lower than
53% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. DCTH: -1625.91 )
DCTH' s 10-Year Net-margin (%) Range
Min: -14990.75   Max: -1625.91
Current: -1625.91

-14990.75
-1625.91
ROE (%) -70.22
DCTH's ROE (%) is ranked higher than
51% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. DCTH: -70.22 )
DCTH' s 10-Year ROE (%) Range
Min: -224.96   Max: -29.56
Current: -70.22

-224.96
-29.56
ROA (%) -56.02
DCTH's ROA (%) is ranked higher than
50% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. DCTH: -56.02 )
DCTH' s 10-Year ROA (%) Range
Min: -157.86   Max: -27.27
Current: -56.02

-157.86
-27.27
ROC (Joel Greenblatt) (%) -794.71
DCTH's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. DCTH: -794.71 )
DCTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -194983.33   Max: -161.78
Current: -794.71

-194983.33
-161.78
EBITDA Growth (3Y)(%) -43.20
DCTH's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. DCTH: -43.20 )
DCTH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -43.2   Max: 56.5
Current: -43.2

-43.2
56.5
EPS Growth (3Y)(%) -44.80
DCTH's EPS Growth (3Y)(%) is ranked higher than
54% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. DCTH: -44.80 )
DCTH' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.8   Max: 93.9
Current: -44.8

-44.8
93.9
» DCTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

DCTH Guru Trades in Q1 2014

Jim Simons Sold Out
» More
Q2 2014

DCTH Guru Trades in Q2 2014

Jim Simons 59,298 sh (New)
» More
Q3 2014

DCTH Guru Trades in Q3 2014

Jim Simons 161,798 sh (+172.86%)
» More
Q4 2014

DCTH Guru Trades in Q4 2014

Jim Simons 260,960 sh (+61.29%)
» More
» Details

Insider Trades

Latest Guru Trades with DCTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.50
DCTH's P/B is ranked higher than
97% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. DCTH: 0.50 )
DCTH' s 10-Year P/B Range
Min: 0.5   Max: 6.18
Current: 0.5

0.5
6.18
P/S 8.49
DCTH's P/S is ranked higher than
50% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. DCTH: 8.49 )
DCTH' s 10-Year P/S Range
Min: 8.5   Max: 1077.33
Current: 8.49

8.5
1077.33
EV-to-EBIT 0.42
DCTH's EV-to-EBIT is ranked higher than
100% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. DCTH: 0.42 )
DCTH' s 10-Year EV-to-EBIT Range
Min: -2.5   Max: 0.6
Current: 0.42

-2.5
0.6
Current Ratio 4.80
DCTH's Current Ratio is ranked higher than
85% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. DCTH: 4.80 )
DCTH' s 10-Year Current Ratio Range
Min: 2.31   Max: 39.15
Current: 4.8

2.31
39.15
Quick Ratio 4.72
DCTH's Quick Ratio is ranked higher than
87% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. DCTH: 4.72 )
DCTH' s 10-Year Quick Ratio Range
Min: 2.31   Max: 39.15
Current: 4.72

2.31
39.15
Days Inventory 703.66
DCTH's Days Inventory is ranked higher than
54% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. DCTH: 703.66 )
DCTH' s 10-Year Days Inventory Range
Min: 669.79   Max: 5170.83
Current: 703.66

669.79
5170.83
Days Sales Outstanding 59.41
DCTH's Days Sales Outstanding is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. DCTH: 59.41 )
DCTH' s 10-Year Days Sales Outstanding Range
Min: 59.41   Max: 161.25
Current: 59.41

59.41
161.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.60
DCTH's Price/Net Cash is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. DCTH: 0.60 )
DCTH' s 10-Year Price/Net Cash Range
Min: 1.38   Max: 16.4
Current: 0.6

1.38
16.4
Price/Net Current Asset Value 0.60
DCTH's Price/Net Current Asset Value is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. DCTH: 0.60 )
DCTH' s 10-Year Price/Net Current Asset Value Range
Min: 1.27   Max: 15.34
Current: 0.6

1.27
15.34
Price/Tangible Book 0.50
DCTH's Price/Tangible Book is ranked higher than
98% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. DCTH: 0.50 )
DCTH' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 44.06
Current: 0.5

0.9
44.06
Price/Median PS Value 0.20
DCTH's Price/Median PS Value is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. DCTH: 0.20 )
DCTH' s 10-Year Price/Median PS Value Range
Min: 0.74   Max: 5.38
Current: 0.2

0.74
5.38
Earnings Yield (Greenblatt) 250.40
DCTH's Earnings Yield (Greenblatt) is ranked higher than
99% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DCTH: 250.40 )
DCTH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 176.9   Max: 8625
Current: 250.4

176.9
8625

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DV3.Germany,
Delcath Systems, Inc., is a Delaware corporation incorporated in August 1988. The Company is a pharmaceutical and medical device company focused on oncology. The Company has directed its research efforts towards the development and clinical study of the Delcath chemosaturation system. The Company's proprietary drug/device combination product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. The Company operates in one business segment, which is the development and commercialization of the Delcath chemosaturation system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the targeted organ. Once the organ is isolated, the Delcath chemosaturation system delivers high doses of chemotherapeutic agents directly to the liver, while limiting systemic exposure and the related side effects by filtering the blood prior to returning it to the patient. The Delcath chemosaturation system involves a series of three catheter insertions, each of which is placed percutaneously through standard interventional radiology techniques. The procedure is minimally invasive and repeatable allowing for multiple courses of treatment with chemotherapeutic drugs and the potential for concomitant cancer therapies. The Company assembles, sterilizes and packages the Delcath chemosaturation system at its facility in Queensbury, New York and has established its European headquarters and distribution facility in Galway, Ireland. It utilizes contract manufacturers to manufacture some components of the Delcath chemosaturation system. The Delcath chemosaturation system competes with all forms of liver cancer treatments. The Delcath chemosaturation system is subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.
» More Articles for DCTH

Headlines

Articles On GuruFocus.com
comment on DCTH Mar 16 2013 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
cooldecency99 note on DCTH May 01 2010 
cooldecency99 note on DCTH May 01 2010 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

More From Other Websites
Most active Nasdaq-traded stocks Mar 31 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 27 2015
Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual... Mar 27 2015
Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual... Mar 27 2015
DELCATH SYSTEMS, INC. Financials Mar 18 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial... Mar 16 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 11 2015
Delcath Reports 2014 Fourth Quarter And Full Year Financial Results Mar 10 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 10 2015
Delcath Reports 2014 Fourth Quarter And Full Year Financial Results Mar 10 2015
Delcath Announces Melphalan/HDS Poster Presentation To Be Presented At The Society Of Surgical... Mar 09 2015
Delcath Announces Melphalan/HDS Poster Presentation To Be Presented At The Society Of Surgical... Mar 09 2015
Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed... Mar 03 2015
Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed... Mar 03 2015
Delcath To Present At The 27th Annual Roth Conference Mar 02 2015
Delcath To Present At The 27th Annual Roth Conference Mar 02 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Feb 18 2015
Delcath Prices $2.8 Million Public Offering of Common Stock and Warrants Feb 11 2015
New York medical device maker plans to invest $2.4 million after stock sale Feb 11 2015
Delcath Prices $2.8 Million Public Offering of Common Stock and Warrants Feb 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK